Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium citrate (67Ga) is a diagnostic radiopharmaceutical developed by the Khlopin Radium Institute for nuclear imaging. It contains the radionuclide Gallium-67, which acts as a biological analog of the ferric ion (Fe3+). Upon intravenous administration, gallium-67 binds to plasma transferrin and is transported to sites of malignancy or inflammation. In tumors, it is internalized via transferrin receptors (CD71) and binds to intracellular proteins such as ferritin and lactoferrin. In inflammatory or pyrogenic processes, it localizes due to increased vascular permeability and binding to lactoferrin released by leukocytes. It is primarily indicated for the visualization of Hodgkin's disease, lymphomas, lung cancer, hepatomas, and various metastases, as well as for the detection of sarcoidosis and acute inflammatory lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium citrate (67Ga).